argenx SE entered a definitive agreement to acquire Forte Biosciences, Inc. for approximately $2.2 billion. The transaction, structured as a cash tender offer, values Forte Biosciences at $77 per share. The acquisition aims to add FB102, an anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, to argenx's immunology pipeline. The deal is expected to close in Q3 2026, subject to customary closing conditions and regulatory approvals. argenx will fund the acquisition entirely from cash on hand. argenx is a global immunology innovation company that develops antibody-based medicines for autoimmune diseases.
